Can You Take Tirzepatide Twice a Week? Understanding Split-Dose Protocols and Why Standard Dosing Works Better

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · 13 sources cited

Key Takeaways

• The Zepbound label (revised 08/2026) gives tirzepatide a half-life of about 5 days, steady-state levels after 4 weeks, and a once-weekly schedule; no other schedule has been studied
• No published clinical trial has tested twice-weekly tirzepatide dosing, and all FDA-approved protocols use once-weekly administration
• Lilly says it cannot make any recommendation on splitting a dose to make smaller or multiple doses because this has not been studied; the label's answer to side effects is a slower escalation or a lower maintenance dose
• Any schedule other than once weekly is off-label and unstudied. The label does allow changing your injection day if at least 72 hours separate two doses, and taking a missed dose within 4 days

The short answer

No. As of September 5, 2026, the Zepbound and Mounjaro labels (both revised 08/2026) specify once-weekly subcutaneous injection, report a half-life of approximately 5 days and steady-state levels after 4 weeks, and allow a change of injection day only when at least 72 hours separate the two doses. Lilly states that it cannot make any recommendation on splitting a dose to make smaller or multiple doses because this has not been studied. Every published SURMOUNT and SURPASS trial used weekly dosing.

Table of contents

1. Why the question comes up: the psychology behind wanting to split doses
2. The pharmacokinetics that make weekly dosing work
3. What the clinical trials actually tested
4. What happens when patients split their weekly dose in half
5. The side-effect assumption: does splitting reduce nausea?
6. The one scenario where twice-weekly dosing appears in practice
7. What most articles get wrong about tirzepatide dosing flexibility
8. The decision tree: when to contact your provider about dosing concerns
9. Comparison with semaglutide: why once-weekly works for both
10. What the label and Lilly say about splitting doses
11. Compounded tirzepatide: what FDA says
12. Corrections, September 2026
13. FAQ
14. Sources

Why the question comes up: the psychology behind wanting to split doses

The impulse to split a weekly medication into smaller, more frequent doses comes from three common mental models, all of which make intuitive sense but misunderstand how tirzepatide works:

Mental model 1: "Smaller doses mean fewer side effects." This assumes side effects correlate with peak plasma concentration. For most oral medications, this is true. For tirzepatide, nobody has tested it. The label lists nausea, diarrhea, vomiting and constipation among the most common adverse reactions and says the majority of these events occurred during dose escalation and decreased over time. Whether two smaller injections would change that has not been studied.

Mental model 2: "More frequent dosing keeps levels more stable." This assumes tirzepatide has a short half-life that creates peaks and troughs. Insulin works this way. Tirzepatide has a half-life of approximately 5 days (5 to 6 days in people with obesity, per the label), a median time to peak concentration of 24 hours (range 8 to 72 hours), and reaches steady-state levels after 4 weeks of once-weekly dosing. The label does not publish a peak-to-trough ratio. Correction, September 2026: an earlier version of this page stated the difference was less than 15%; that figure could not be traced to any published source and has been removed.

Mental model 3: "I can customize the protocol to fit my body." This reflects the broader cultural shift toward personalized medicine, which is valuable in many contexts. But tirzepatide dosing is not a parameter that benefits from personalization. The weekly schedule is not arbitrary. It follows from the medication's half-life, which the label attributes to a C20 fatty diacid that enables albumin binding and prolongs the half-life (Zepbound label, section 12.1). An earlier version of this page described a polyethylene glycol modification; tirzepatide is not PEGylated and that wording has been corrected.

The question "Can I take it twice a week?" is almost always a proxy for "I am having side effects and want more control." The answer to the underlying concern is dose adjustment or symptom management, not schedule modification.

The pharmacokinetics that make weekly dosing work

Tirzepatide is a peptide with a C20 fatty diacid (1,20-eicosanedioic acid) attached through a linker; its molecular weight is 4813.53 Da. According to the Zepbound label, the fatty diacid enables albumin binding (tirzepatide is about 99% bound to plasma albumin), which prolongs the half-life.

The result is a half-life of approximately 5 days (120 hours) after subcutaneous injection. Half-life is the time it takes for plasma concentration to decrease by 50%. After one half-life, 50% remains. After two half-lives (10 days), 25% remains. After three half-lives (15 days), 12.5% remains.

This means that if you inject 5 mg of tirzepatide on Monday:

• By Saturday (day 5), approximately 2.5 mg equivalent remains in circulation
• By the following Monday (day 7), approximately 1.9 mg equivalent remains
• When you inject the next 5 mg dose on Monday, it adds to the 1.9 mg still circulating

By week 4 of consistent weekly dosing, you reach steady state, where the amount you inject each week equals the amount eliminated. The label states that steady-state plasma concentrations are achieved following 4 weeks of once-weekly administration.

The label's pharmacokinetic section (revised 08/2026) gives the numbers that matter: median time to maximum concentration 24 hours (range 8 to 72 hours), mean absolute bioavailability 80%, elimination half-life approximately 5 days, steady state after 4 weeks, and dose-proportional exposure across the 2.5 to 15 mg range.

Correction, September 2026: an earlier version of this page cited a 2021 pharmacokinetic study of 89 volunteers reporting a steady-state peak-to-trough ratio of 1.17. No such study could be found and the figure has been removed. No published study has compared once-weekly with split dosing, so any statement about the benefit or harm of splitting is theory, not evidence.

What the clinical trials actually tested

Every published tirzepatide clinical trial used once-weekly subcutaneous dosing. There is no published evidence base for twice-weekly administration.

Trial	Population	Dosing schedule	Duration	N
SURMOUNT-1	Obesity without diabetes	Once weekly, escalating from 2.5 mg to 15 mg	72 weeks	2,539
SURMOUNT-2	Obesity with diabetes	Once weekly, escalating from 2.5 mg to 15 mg	72 weeks	938
SURMOUNT-3	Obesity after initial weight loss	Once weekly, 10 mg or 15 mg maintenance	72 weeks	579
SURMOUNT-4	Obesity, withdrawal study	Once weekly, 10 mg or 15 mg vs placebo	52 weeks	670
SURPASS-1	Type 2 diabetes, monotherapy	Once weekly, 5 mg, 10 mg, or 15 mg	40 weeks	478
SURPASS-2	Type 2 diabetes vs semaglutide	Once weekly, 5 mg, 10 mg, 15 mg vs semaglutide 1 mg	40 weeks	1,879
SURPASS-3	Type 2 diabetes, add-on to metformin	Once weekly, 5 mg, 10 mg, 15 mg vs insulin degludec	52 weeks	1,444
SURPASS-4	Type 2 diabetes, cardiovascular outcomes	Once weekly, 5 mg, 10 mg, 15 mg vs insulin glargine	104 weeks	2,002
SURPASS-5	Type 2 diabetes, add-on to insulin glargine	Once weekly, 5 mg, 10 mg, 15 mg	40 weeks	475

The escalation schedule in the Zepbound label (revised 08/2026):

• Start at 2.5 mg once weekly for 4 weeks
• After 4 weeks, increase to 5 mg once weekly
• Increase in 2.5 mg increments only after at least 4 weeks on the current dose
• Recommended maintenance dosages are 5 mg, 10 mg or 15 mg once weekly; 15 mg is the maximum
• If a maintenance dosage is not tolerated, the label says to consider a lower maintenance dosage

No trial tested 1.25 mg twice weekly, 2.5 mg twice weekly, or any other split-dose protocol. The FDA approval for Zepbound (brand tirzepatide) and Mounjaro (brand tirzepatide for diabetes) specifies once-weekly administration. Compounded tirzepatide is not FDA-approved and was not studied in these trials; providers generally follow the approved once-weekly schedule.

What happens when patients split their weekly dose in half

Despite the lack of evidence, some patients attempt to split their weekly dose into two smaller injections, typically spaced 3 to 4 days apart. The rationale is usually "I want to avoid the nausea spike on injection day."

There is no pharmacokinetic study of split dosing to point to. Lilly's position, in a 2026 medical FAQ on the Mounjaro KwikPen, is that it cannot make any recommendations on splitting the pen to make smaller or multiple doses because this has not been studied.

What does change:

• More injections. Two injections a week means twice as many injection sites. Injection site reactions are among the most common adverse reactions in the Zepbound label.
• Doses that cannot be split cleanly. Zepbound single-dose pens and single-dose vials hold one full weekly dose, and the KwikPen dials fixed doses; none is designed to deliver half a dose.
• A different routine from the one the rules are built for. The label's missed-dose rule (within 4 days) and day-change rule (at least 72 hours between doses) assume once-weekly dosing.

Correction, September 2026: an earlier version of this page described a 2023 Cleveland Clinic chart review of 47 patients presented at an Obesity Medicine Association meeting, and a FormBlends observation about patients returning to weekly dosing. Neither could be verified, and both have been removed. We are not aware of any published data on what happens when patients split tirzepatide doses.

The side-effect assumption: does splitting reduce nausea?

The most common reason patients ask about twice-weekly dosing is nausea. The assumption is that a smaller dose will cause less nausea.

This assumption is wrong, but understandably so. It conflates two different types of nausea:

Type 1: Acute injection-related nausea. This occurs within 1 to 6 hours of injection and is thought to result from a transient spike in GLP-1 receptor activation in the area postrema (the brain's vomiting center). The label does not separate this from other nausea. It lists nausea among the adverse reactions reported in 5% or more of patients and notes that most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. An earlier version of this page gave a figure of less than 2% from SURMOUNT-1; that figure is not in the trial report and has been removed.

Type 2: Sustained nausea from delayed gastric emptying. This is the common nausea patients experience on GLP-1 medications. It results from the medication's therapeutic mechanism (slowing gastric emptying) and persists as long as therapeutic plasma levels are maintained. This nausea peaks during dose escalations and usually improves after 2 to 4 weeks at a stable dose as the stomach adapts.

Whether splitting a weekly dose changes this nausea has not been studied, so there is no evidence that it helps. The label's own tools for it are a slower escalation and a lower maintenance dose.

The correct intervention for dose-escalation nausea is not schedule modification. It is:

• Slowing the escalation: the label requires at least 4 weeks at each step before increasing and does not set a maximum time at a step
• Eating smaller, more frequent meals
• Avoiding high-fat foods that delay gastric emptying further
• Using ginger, vitamin B6, or prescription antiemetics (ondansetron, metoclopramide) during the adaptation window
• If a maintenance dosage is not tolerated, the label says to consider a lower maintenance dosage, which your provider can arrange

These interventions address the mechanism. Splitting the dose does not.

The one scenario where twice-weekly dosing appears in practice

Any schedule other than once weekly is off-label and unstudied. Lilly's medical information team states that it cannot make any recommendations on splitting a dose to make smaller or multiple doses because this has not been studied (Lilly medical FAQ, Mounjaro KwikPen, 2026).

Correction, September 2026: an earlier version of this page described a 1.25 mg twice-weekly micro-titration practice and reported anecdotal results from it. That description was not sourced and has been removed. The labeled options for a patient who cannot tolerate a dose are to stay at the current step longer (the label requires at least 4 weeks at each step and sets no maximum) or to use a lower maintenance dosage.

If your provider suggests twice-weekly dosing, ask:

• What is the clinical rationale specific to my case?
• What is the plan to transition back to weekly dosing?
• What evidence supports this approach?
• What are the risks of staying on a non-standard schedule long-term?

These are fair questions. Off-label prescribing is legal and sometimes necessary, but it should be intentional and explained.

What most articles get wrong about tirzepatide dosing flexibility

Most patient-facing articles on tirzepatide dosing include a sentence like "Talk to your doctor about adjusting your dose or schedule to fit your needs." This is well-intentioned but misleading.

The error: it implies that dosing schedule is a flexible parameter, like the time of day you take a medication. It is not. The weekly schedule is the one the label and every published trial are built on. No study has tested whether a different schedule changes the therapeutic effect or the side effects, and Lilly says it cannot recommend splitting doses.

The correct statement is: "Talk to your doctor about adjusting your dose or slowing your titration schedule to manage side effects." Dose and titration speed are the flexible parameters. Schedule is not.

This distinction matters because patients who believe schedule is flexible often experiment on their own, leading to confusion, missed doses, and ultimately discontinuation. Correction, September 2026: an earlier version of this page cited a 2024 study reporting a 2.3-fold higher discontinuation rate among patients who changed their schedule on their own. No such study could be found and it has been removed.

The other common error: conflating tirzepatide with insulin. Insulin analogs (glargine, detemir, degludec) are often dosed daily, twice daily, or even more frequently depending on the formulation. Patients with diabetes who have used insulin sometimes assume all injectable medications follow similar flexible schedules. They do not. Tirzepatide is not insulin. It is a peptide hormone analog with a fundamentally different pharmacokinetic profile.

The decision tree: when to contact your provider about dosing concerns

Use this decision tree if you are considering modifying your tirzepatide schedule:

Are you experiencing side effects (nausea, vomiting, reflux, constipation, fatigue)?

• Yes → Go to next question.
• No, I just want more control over my schedule → Do not modify your schedule. Weekly dosing is the only studied and labeled schedule for this medication.

Have you been at your current dose for less than 4 weeks?

• Yes → Side effects during the first 4 weeks are expected and usually improve. Use symptom-management strategies (small frequent meals, ginger, B6, avoid high-fat foods). Contact your provider if symptoms are severe (vomiting more than twice per day, inability to keep down fluids, severe abdominal pain). Do not modify your schedule.
• No, I have been at this dose for 4+ weeks → Go to next question.

Are your side effects interfering with daily function (missing work, unable to eat, losing weight too rapidly)?

• Yes → Contact your provider within 24 to 48 hours. The appropriate intervention is dose reduction, not schedule modification. Your provider may step you back to the previous dose or pause escalation.
• No, side effects are bothersome but manageable → Ask your provider about staying at the current dose longer; the label requires at least 4 weeks at each step and allows a lower maintenance dosage if a dose is not tolerated. Use symptom-management strategies. Do not modify your schedule.

Has your provider specifically recommended twice-weekly dosing as an off-label strategy?

• Yes → Follow your provider's instructions and ask the questions listed in the previous section.
• No → Do not split your dose. Contact your provider to discuss dose adjustment or titration speed.

Comparison with semaglutide: why once-weekly works for both

Semaglutide (Ozempic, Wegovy, and compounded versions) is the other major GLP-1 receptor agonist used for weight loss. It is also dosed once weekly. The question "Can I take it twice a week?" comes up for semaglutide as well.

The answer is the same, for the same reason: half-life.

Parameter	Tirzepatide	Semaglutide
Half-life	~5 days (120 hours)	~7 days (168 hours)
Time to steady state	~4 weeks	~4 to 5 weeks
Missed-dose window (label)	Within 4 days (96 hours)	Within 5 days
Minimum gap when changing injection day (label)	72 hours	48 hours
Approved dosing schedule	Once weekly	Once weekly
Published trials testing twice-weekly dosing	0	0

Semaglutide's half-life is even longer than tirzepatide's (approximately 1 week per the Ozempic label, with steady state after 4 to 5 weeks). Its label allows a change of injection day when at least 2 days (48 hours) separate doses, and a missed dose can be taken within 5 days.

Both medications achieve stable plasma levels with weekly dosing. Both have been extensively studied on weekly schedules. Neither benefits from splitting doses.

Daily GLP-1 medicines such as liraglutide (Saxenda, Victoza) exist because of their much shorter half-lives; liraglutide's label gives about 13 hours. The difference is not the drug class. It is the half-life.

What the label and Lilly say about splitting doses (as of September 5, 2026)

The Zepbound prescribing information (revised 08/2026) is the primary source for everything on this page, and it says nothing about splitting a dose. What it does say:

• Inject once weekly, at any time of day, with or without meals.
• Start at 2.5 mg for 4 weeks, then 5 mg; increase in 2.5 mg increments only after at least 4 weeks on the current dose; maintenance dosages are 5, 10 or 15 mg.
• If a maintenance dosage is not tolerated, consider a lower maintenance dosage.
• A missed dose can be taken within 4 days (96 hours); after that, skip it and take the next dose on the regular day.
• The injection day can be changed if at least 3 days (72 hours) separate the two doses.
• Half-life is approximately 5 days; steady-state concentrations are reached after 4 weeks of once-weekly dosing.

Lilly's medical information team, answering the question directly for the Mounjaro KwikPen in a document dated 07/2026, says it cannot make any recommendations on splitting the pen to make smaller or multiple doses because this has not been studied. The same active ingredient and the same label logic apply to Zepbound.

The presentations also matter. Zepbound single-dose pens and single-dose vials (2.5 mg to 15 mg in 0.5 mL) hold one weekly dose. The multi-dose vial and the four-dose KwikPen hold four weekly doses at a fixed strength, and the label says never to share a KwikPen even if the pen needle is changed. None of them is designed to deliver half a dose.

Compounded tirzepatide: what FDA says (as of September 5, 2026)

Compounded tirzepatide is not FDA-approved, has not been through the SURMOUNT or SURPASS trials, and has no label of its own, so no split-dose schedule has been studied for it either. FDA declared the tirzepatide shortage resolved on December 19, 2024 (and the semaglutide shortage on February 21, 2025), and reports that as of May 31, 2026 it had received more than 730 adverse event reports involving compounded tirzepatide and 990 involving compounded semaglutide, some of them dosing errors. If you use a compounded product, follow the once-weekly schedule your provider prescribed and the pharmacy's units-per-dose instructions exactly.

Corrections, September 2026

Correction, September 2026: an earlier version of this page stated a steady-state peak-to-trough ratio of 1.17 from a 2021 study of 89 volunteers, a peak-to-trough difference of less than 15%, an acute nausea rate below 2% in SURMOUNT-1, a 2023 Cleveland Clinic chart review of 47 patients, a 2024 study showing a 2.3-fold higher discontinuation rate, and a 1.25 mg twice-weekly micro-titration practice. None of these could be traced to any published source and all have been removed. The page also described tirzepatide as PEGylated; the label describes a C20 fatty diacid attached through a linker. The pharmacokinetic and dosing statements now come from the Zepbound and Mounjaro labels revised 08/2026 and Lilly's 2026 medical FAQ on dose splitting.

FAQ

Can you take tirzepatide twice a week instead of once?

No. The Zepbound label specifies once-weekly injection, twice-weekly dosing has not been studied, and Lilly says it cannot recommend splitting a dose to make smaller or multiple doses. If side effects are the reason you are asking, the label's answer is a slower escalation or a lower maintenance dosage, arranged with your provider.

Does splitting tirzepatide into two doses reduce nausea?

There is no evidence that it does, because no study has compared split with once-weekly dosing. The Zepbound label lists nausea among the most common adverse reactions and says most nausea events occurred during dose escalation and decreased over time. The labeled ways to manage it are to stay at a dose step longer or use a lower maintenance dosage.

What if I miss my weekly tirzepatide injection?

If you miss your injection and it has been less than 4 days since your scheduled day, take the missed dose as soon as you remember. If it has been more than 4 days, skip the missed dose and take the next dose on your regular day (Zepbound label, revised 08/2026). Do not double up. Contact your provider if you miss two consecutive doses.

Can I take tirzepatide every 3 days or every 5 days?

No. The approved and studied schedule is once every 7 days. The label allows you to change your injection day as long as at least 72 hours separate the two doses, but that is for moving your day, not for a shorter regular interval. More frequent dosing has not been studied for safety or efficacy.

Why do some people say they feel better on twice-weekly tirzepatide?

Nobody knows, because it has not been studied; individual reports are not evidence either way. If you feel worse on the labeled schedule, tell your provider. The label allows a slower escalation (at least 4 weeks per step, with no maximum) and a lower maintenance dosage if a dose is not tolerated.

Is twice-weekly dosing safer than once-weekly dosing?

Unknown. Twice-weekly dosing has not been studied, so its safety cannot be compared with the once-weekly schedule tested in the SURMOUNT and SURPASS trials. It does mean twice as many injections, and injection site reactions are among the most common adverse reactions in the Zepbound label.

Can I take tirzepatide on different days each week?

It is best to inject on the same day each week to maintain consistent plasma levels and build a routine. If you need to change your injection day, the Zepbound label allows it as long as at least 3 days (72 hours) separate the two doses; then continue weekly from the new day. Avoid frequent day changes.

What is the shortest interval between tirzepatide injections?

The prescribing information for Zepbound (revised 08/2026) specifies a minimum of 72 hours (3 days) between doses if you need to change your injection day. Do not inject more frequently than every 3 days. For routine dosing, stick to 7-day intervals.

Does compounded tirzepatide have a different dosing schedule than brand-name Zepbound?

Compounded tirzepatide is not FDA-approved and its pharmacokinetics have not been studied, so there is no separate schedule to point to; providers generally follow the approved once-weekly schedule. FDA had received more than 730 adverse event reports involving compounded tirzepatide as of May 31, 2026. Follow your provider's instructions.

Can I inject tirzepatide in the morning one week and evening the next?

Yes. The time of day does not matter. What matters is the 7-day interval. Some patients prefer morning injections to monitor for side effects during the day. Others prefer evening injections to sleep through any acute nausea. Choose what works for you and stay consistent.

What should I do if my provider suggests twice-weekly tirzepatide dosing?

Ask why they are recommending a non-standard schedule, what evidence supports it, and what the plan is to transition back to weekly dosing. Off-label prescribing is sometimes appropriate, but it should be explained and intentional.

Is there any research on twice-weekly tirzepatide dosing?

No. All published tirzepatide clinical trials used once-weekly dosing. There are no peer-reviewed studies testing twice-weekly protocols. Any twice-weekly dosing in practice is off-label experimentation without an evidence base.

Can I split my Zepbound or Mounjaro dose to twice a week?

Lilly says no recommendation can be made because splitting has not been studied (Lilly medical FAQ on the Mounjaro KwikPen, 2026). The labels for both products, revised 08/2026, specify once-weekly injection and give two tools for tolerability problems: stay at a dose step for longer than the 4-week minimum, or use a lower maintenance dosage. Talk to your provider before changing anything.

Can you take 2.5 mg of tirzepatide twice a week instead of 5 mg once?

This has not been studied and is not a labeled regimen. The Zepbound label (revised 08/2026) uses 2.5 mg only as the once-weekly starting dose for the first 4 weeks, then moves to 5 mg once weekly. If 5 mg is not tolerated, the label's option is to consider a lower maintenance dosage with your provider, not a split schedule. Single-dose pens and vials hold one full dose and cannot deliver half.

What does the label say to do if a tirzepatide dose is not tolerated?

Two things. First, the dose can be increased only after at least 4 weeks on the current dose, and the label sets no maximum time at a step, so escalation can be slowed. Second, if a maintenance dosage is not tolerated, the label says to consider a lower maintenance dosage (Zepbound prescribing information, revised 08/2026). Both are decisions for your prescriber.

Related guides

• Semaglutide Twice a Week: Why the Standard Schedule Exists, When Deviations Work, and the Data on Split Dosing
• How Much Tirzepatide Per Week: The Standard Titration Schedule, When to Escalate, and What Dose Actually Works
• Do You Take Sermorelin 7 Days a Week? The Dosing Schedule That Actually Works
• Can I Take Mounjaro Every Other Week? The Pharmacokinetic Reality and When Dose Spacing Actually Works
• Can You Take Semaglutide Twice a Week? The Pharmacokinetic Reality and the Rare Exception
• Tirzepatide vs Semaglutide: Which Works Better?
• Tool: dosage calculator

Sources

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Diabetes Care. 2023.
3. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
6. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
7. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021.
8. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
9. Eli Lilly and Company. Zepbound (tirzepatide) injection, US prescribing information, revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
10. Eli Lilly and Company. Mounjaro (tirzepatide) injection, US prescribing information, revised 08/2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
11. Eli Lilly and Company. Medicine FAQ: Can the Mounjaro KwikPen be split into smaller doses? Document dated 07/2026. https://www.lilly.com/en-ca/medicines/medicine-faqs/mounjaro-kwikpen/smaller-doses
12. Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information, revised 05/2026. https://www.novo-pi.com/ozempic.pdf
13. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss, adverse event counts as of May 31, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Saxenda, and Victoza are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.